Addressing circadian rhythm disturbances in depressed patientsDivision of Clinical Neuroscience, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada r.lam{at}ubc.ca Abstract Desynchronisation of normal circadian rhythms, including the sleep–wake rhythm, is common in major depressive disorder (MDD). The association between sleep disturbances and depression has long been recognised. Disturbed sleep is a diagnostic criterion for MDD, and insomnia commonly precedes the onset of symptomatic mood disorders. Disruptions of the sleep–wake cycle (sleep architecture and timing) are residual symptoms that may prevent the attainment of high-quality remission and delay recovery from MDD. Therefore, early recognition and treatment of sleep disturbances may be important for the treatment and prevention of recurrent depression. Evidence suggests that melatonergic (MT1 and MT2) and the 5-HT2C serotonergic receptor subtypes are important modulators of circadian rhythmicity. Agomelatine is the first melatonergic antidepressant; an agonist of melatonin MT1 and MT2 receptors, with additional antagonist properties at the 5-HT2C receptors. Agomelatine combines antidepressant efficacy including quality and efficiency of sleep, with a more favourable side-effect profile than current antidepressant treatments, including neutral effects on sexual function, bodyweight and the absence of discontinuation symptoms. These positive features provide a novel approach to the treatment of depression and the attainment of high-quality remission in MDD.
Key Words: agomelatine • circadian rhythm disturbances • major depressive disorder • recovery • remission • residual symptoms
Journal of Psychopharmacology, Vol. 22, No. 7 suppl,
13-18 (2008) This article has been cited by other articles:
|
|||||||||||||||||
